ImmunoGen Announces Conference Call to Discuss Its First Quarter 2019 Operating Results
Thursday, April 18, 2019 4:30:00 PM ET
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, May 3, 2019 to discuss its first quarter operating results. Management will also provide a brief update on the business.
Conference Call Information
To access the live call by phone, dial 323-994-2093; the conference ID is 8980567. The call may also be accessed through the Investors and Media section of the Company’s website, www.immunogen.com . Following the webcast, a replay of the call will be available at the same location through May 17, 2019.
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to “target a better now.” The Company has built a productive platform generating a broad pipeline of ADCs targeting solid tumors and hematologic malignancies.
Learn more about who we are, what we do, and how we do it at www.immunogen.com .
INVESTOR RELATIONS CONTACT
Source: ImmunoGen, Inc.